213 Sentinel lymph node biopsy in patients with clinical stage IIB/C cutaneous melanoma

Recent approval of adjuvant anti-PD1 therapy for patients with pathologic stage IIB/C cutaneous melanoma has led to questioning whether sentinel lymph node biopsy (SLNB) is necessary clinical disease. We sought evaluate the prognostic significance SLNB in across T-stages using logistic regression and propensity matching, a technique that not been utilized previously examine this issue. Immune checkpoint inhibitor naïve were identified from Surveillance, Epidemiology End Results database (2004-2011). Patients regional positivity (LN+) compared LN- multivariable regression. Propensity matching was performed, 5-year disease-specific survival (DSS) estimated. Of 9,018 evaluated, 6,219 (69.0%) underwent LN evaluation, which 1,989 LN+ (32.0%). Among who SLNB, factors associated Asian American/Pacific Islander race (OR 2.83, p<0.001), truncal 1.74, p<0.001) or extremity 1.55, tumor location, acral lentiginous histology p=0.002), increasing thickness 1.00, ulceration 1.73, younger age 1.02, p<0.001). After undergoing significantly reduced DSS (52.6% vs. 77.5% LN-, Notably, remained different T-stages: T3b (53.5% 64.8% p=0.001), T4a (56.0% 72.2% T4b (35.3% 59.7% Performance difference matched cohort (62.7% performed 60.3% no p=0.394). For melanoma, status provides invaluable information can be an important factor collective decision-making regarding administration based on risk assessment.